PHP
AMRX icon

Parkman Healthcare Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Parkman Healthcare Partners’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.37M Buy
541,190
+240,438
+80% +$3.29M 0.96% 43
2026
Q1 		$3.74M Buy
+300,752
New +$4.04M 0.39% 69

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Parkman Healthcare Partners's AMRX Position: Q2 2026 in Review

Parkman Healthcare Partners increased its Amneal Pharmaceuticals (AMRX) stake by 80% in Q2 2026, buying an estimated $3.29M and bringing the position to 541,190 shares worth $9.37M. The position accounts for 0.96% of the portfolio, ranked #43.

Parkman Healthcare Partners first reported a position in AMRX in Q1 2026 and has held it in 2 quarters since. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Parkman Healthcare Partners held 541,190 shares of Amneal Pharmaceuticals worth $9.37M as of Q2 2026.
  • Parkman Healthcare Partners bought 240,438 Amneal Pharmaceuticals shares in Q2 2026, an estimated $3.29M.
  • Amneal Pharmaceuticals made up 0.96% of Parkman Healthcare Partners's portfolio in Q2 2026, its #43 holding.
  • Parkman Healthcare Partners first reported a position in Amneal Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.